SCHEMBL4072402

SCHEMBL4072402

OCc1cccc(-c2cc3ncnc(NCCc4ccc(O)cc4)c3s2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.48
NR2F2 P24468 1/20 0.47
FLT1 P17948 6/20 0.46
EGFR P00533 6/20 0.46
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
AURKA O14965 1/20 0.43
PIP4K2C Q8TBX8 1/20 0.43
IKBKB O14920 1/20 0.43
CHUK O15111 1/20 0.43
TTBK1 Q5TCY1 1/20 0.42
TTBK2 Q6IQ55 1/20 0.42
RIPK2 O43353 1/20 0.42
TYK2 P29597 1/20 0.41
LMNA P02545 1/20 0.41
APP P05067 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071814 0.90 FLT1 (0.55) HTTNR2F2FLT1EGFRRAB9A
SCHEMBL4068423 0.88 MAP3K8 (0.51) HTTNR2F2FLT1EGFRRAB9A
SCHEMBL4071720 0.85 CYP1A2 (0.47) HTTNR2F2FLT1EGFRRAB9A
SCHEMBL4075888 0.85 FLT1 (0.48) HTTNR2F2FLT1EGFRRAB9A
SCHEMBL4067658 0.84 FLT1 (0.61) HTTFLT1EGFRRAB9ANPC1
SCHEMBL3937824 0.82 STK17B (0.58) HTTNR2F2FLT1EGFRAURKA
SCHEMBL4071318 0.81 EGFR (0.52) HTTFLT1EGFRRAB9ANPC1
SCHEMBL4072529 0.79 TYK2 (0.60) HTTFLT1EGFRRAB9ANPC1
SCHEMBL4006556 0.79 HTT (0.50) HTTNR2F2FLT1EGFRRAB9A
SCHEMBL3929003 0.79 LMNA (0.49) HTTFLT1EGFRRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007422-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 HTT 3455/4885NR2F2 1415/4885FLT1 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.